{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:10:29Z","timestamp":1784304629653,"version":"3.55.0"},"reference-count":196,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite notable progress in managing B-cell acute lymphoblastic leukemia (B-ALL) over recent decades, particularly in pediatric cohorts where the 5-year overall survival (OS) reaches 90%, outcomes for the 10\u201315% with relapsed and refractory disease remain unfavorable. This disparity is further accentuated in adults, where individuals over the age of 40 years undergoing aggressive multiagent chemotherapy continue to have lower survival rates. While the adoption of pediatric-inspired treatment protocols has enhanced complete remission (CR) rates among younger adults, 20\u201330% of these patients experience relapse, resulting in a subsequent 5-year OS rate of 40\u201350%. For relapsed B-ALL in adults, there is no universally accepted standard salvage therapy, and the median OS is short. The cornerstone of B-ALL treatment continues to be the utilization of combined cytotoxic chemotherapy regimens to maximize early and durable disease control. In this manuscript, we go beyond the multiagent chemotherapy medications developed prior to the 1980s and focus on the incorporation of antibody-based therapy for B-ALL with an eye on existing and upcoming approved indications for blinatumomab, inotuzumab ozogamicin, other monoclonal antibodies, and chimeric antigen receptor (CAR) T cell products in frontline and relapsed\/refractory settings. In addition, we discuss emerging investigational therapies that harness the therapeutic vulnerabilities of the disease through targeting apoptosis, modifying epigenetics, and inhibiting the mTOR pathway.<\/jats:p>","DOI":"10.3390\/cancers17050779","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:45:08Z","timestamp":1740469508000},"page":"779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-8854","authenticated-orcid":false,"given":"Clifford M.","family":"Csizmar","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7336","authenticated-orcid":false,"given":"Antoine N.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"ref_3","unstructured":"National Cancer Institute (2023). SEER*Explorer: An Interactive Website for SEER Cancer Statistics [Internet]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980\u20132017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Stanze","year":"2012","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Dombret","year":"2016","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2018-10-882142","article-title":"PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome","volume":"133","author":"Passet","year":"2019","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature13115","article-title":"Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia","volume":"508","author":"Li","year":"2014","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nm1253","article-title":"Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia","volume":"11","author":"Castor","year":"2005","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s43018-022-00370-5","article-title":"Acute lymphoblastic leukemia displays a distinct highly methylated genome","volume":"3","author":"Hetzel","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia","volume":"386","author":"Chiaretti","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Global approach to the diagnosis of leukemia using gene expression profiling","volume":"106","author":"Haferlach","year":"2005","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1158\/1078-0432.CCR-04-2165","article-title":"Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation","volume":"11","author":"Chiaretti","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.15251","article-title":"Rapid identification of BCR\/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: Clinical, prognostic and therapeutic implications","volume":"181","author":"Chiaretti","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern Therapy of Acute Lymphoblastic Leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3324\/haematol.2012.081877","article-title":"The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)\/MLL-AFF1 prospectively treated in the UKALLXII\/ECOG2993 trial","volume":"98","author":"Marks","year":"2013","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2017-05-783852","article-title":"Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Baranger","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome\u2013Negative Precursor B-Lineage Acute Lymphoblastic Leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): A phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: A single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome\u2013Negative B-Cell Acute Lymphoblastic Leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph\/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial","volume":"142","author":"Goekbuget","year":"2023","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2023-174973","article-title":"Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial","volume":"142","author":"Chiaretti","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2022-166035","article-title":"Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): Results of the EWALL-INO study","volume":"140","author":"Chevallier","year":"2022","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome\u2013Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: Long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.33655","article-title":"Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2021-146214","article-title":"Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): Results of the ongoing GMALL bold trial","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2022-158934","article-title":"Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph\/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"key":"ref_53","first-page":"8","article-title":"Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab front-line trial for newly diagnosed adult Ph-negative B-lineage ALL patients","volume":"5","author":"Bassan","year":"2021","journal-title":"HemaSphere"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin \u03b31I: An Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"Dombret","year":"2019","journal-title":"Hematology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"Zugmaier","year":"2017","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Zugmaier","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u22124 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2021-146306","article-title":"First results of the risk-adapted, MRD-stratified GMALL trial 08\/2013 in 705 adults with newly diagnosed acute lymphoblastic leukemia\/lymphoma (ALL\/LBL)","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: A single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2022-159397","article-title":"Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014\/B Study","volume":"140","author":"Boissel","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/bloodadvances.2023012139","article-title":"Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission","volume":"8","author":"Urbino","year":"2024","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: A phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.3324\/haematol.2016.159905","article-title":"Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed\/refractory CD22-positive precursor B-cell acute lymphocytic leukemia","volume":"102","author":"Chevallier","year":"2017","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2024.0967","article-title":"Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial","volume":"10","author":"Kopmar","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","article-title":"Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia","volume":"24","author":"Short","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"106283","DOI":"10.1016\/j.leukres.2019.106283","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: Outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e836","DOI":"10.1016\/j.clml.2022.04.022","article-title":"Time to First Subsequent Salvage Therapy in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial","volume":"22","author":"Stelljes","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.33469","article-title":"Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"127","author":"Jabbour","year":"2021","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Fracchiolla, N.S., Scium\u00e8, M., Papayannidis, C., Vitale, A., Chiaretti, S., Annunziata, M., Giglio, F., Salutari, P., Forghieri, F., and Lazzarotto, D. (2023). Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. Cancers, 15.","DOI":"10.3390\/cancers15184623"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","article-title":"Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia","volume":"35","author":"Wei","year":"2021","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.23901","article-title":"Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody","volume":"90","author":"Jabbour","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/bloodadvances.2023012430","article-title":"Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed\/refractory ALL","volume":"8","author":"Zhao","year":"2024","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs. Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs. Imatinib in Frontline Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3904\/kjim.2022.401","article-title":"Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: A prospective phase II study","volume":"38","author":"Baek","year":"2023","journal-title":"Korean J. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","volume":"42","author":"Bassan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: A US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2023-180204","article-title":"Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)","volume":"142","author":"Advani","year":"2023","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26622","article-title":"Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"98","author":"Paul","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2020.1762876","article-title":"Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the real-life OPAL study","volume":"61","author":"Tavitian","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome\u2013Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"E379","DOI":"10.1002\/ajh.26281","article-title":"Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study","volume":"96","author":"Jabbour","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","article-title":"Blinatumomab\u2009+\u2009ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"62","author":"Couturier","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: A phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.24.00500","article-title":"Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia","volume":"42","author":"Yoshimura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome\u2013like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2023-190495","article-title":"Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children\u2019s Oncology Group AALL1131","volume":"142","author":"Salzer","year":"2023","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521\/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","article-title":"A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"16","author":"Kantarjian","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","article-title":"Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.14806","article-title":"A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia","volume":"182","author":"Short","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.2011.08762.x","article-title":"A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia","volume":"154","author":"Schindler","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13063-022-06982-7","article-title":"Safety of AFM11 in the treatment of patients with B-cell malignancies: Findings from two phase 1 studies","volume":"24","author":"Topp","year":"2023","journal-title":"Trials"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1200\/JCO.2024.42.16_suppl.6505","article-title":"Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1002\/cncr.33796","article-title":"A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed\/refractory B-precursor cell acute lymphoblastic leukemia","volume":"127","author":"Klisovic","year":"2021","journal-title":"Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/bloodadvances.2020002403","article-title":"Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia","volume":"4","author":"Cassaday","year":"2020","journal-title":"Blood Adv."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2011-11-390781","article-title":"Trastuzumab for treatment of refractory\/relapsed HER2-positive adult B-ALL: Results of a phase 2 GRAALL study","volume":"119","author":"Chevallier","year":"2012","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed\/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ajh.27289","article-title":"A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study","volume":"99","author":"Tang","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1080\/10428194.2016.1263843","article-title":"Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed\/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia","volume":"58","author":"Vey","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"106707","DOI":"10.1016\/j.leukres.2021.106707","article-title":"Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia","volume":"110","author":"Carraway","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","article-title":"A Phase I\/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"21","author":"Daver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"21229","DOI":"10.1002\/cam4.6701","article-title":"A phase 2 and pharmacological study of sapanisertib in patients with relapsed and\/or refractory acute lymphoblastic leukemia","volume":"12","author":"Aldoss","year":"2023","journal-title":"Cancer Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ajh.24568","article-title":"Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias","volume":"92","author":"Ragon","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1078-0432.CCR-10-1878","article-title":"A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias","volume":"17","author":"Lancet","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"107075","DOI":"10.1016\/j.leukres.2023.107075","article-title":"A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Wilde","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.26105","article-title":"Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia","volume":"96","author":"Jonas","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2020003368","article-title":"Bortezomib and rituximab in de novo adolescent\/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia","volume":"5","author":"Jain","year":"2021","journal-title":"Blood Adv."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13050","article-title":"Safety and clinical activity of 5-aza-2\u2032-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed\/refractory acute lymphocytic leukaemia","volume":"167","author":"Benton","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.2023021088","article-title":"The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis","volume":"143","author":"Lenk","year":"2024","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"106385","DOI":"10.1016\/j.leukres.2020.106385","article-title":"Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study","volume":"95","author":"Goldberg","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1200\/JCO.2022.40.16_suppl.10024","article-title":"Menin inhibitors as targeted therapeutics in KMT2a rearranged infant leukemia and the identification of effective treatment combinations","volume":"40","author":"Sharma","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Yang","year":"2008","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.bneo.2024.100015","article-title":"Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells","volume":"1","author":"Imanaga","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e27062","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14569","article-title":"A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: A Children\u2019s Oncology Group study (ADVL1114)","volume":"177","author":"Rheingold","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature07185","article-title":"Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery","volume":"455","author":"Lindqvist","year":"2008","journal-title":"Nature"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.1157425","article-title":"Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry","volume":"320","author":"Seki","year":"2008","journal-title":"Science"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-18-2675","article-title":"A Phase II Study of Alisertib in Children with Recurrent\/Refractory Solid Tumors or Leukemia: Children\u2019s Oncology Group Phase I and Pilot Consortium (ADVL0921)","volume":"25","author":"Fox","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1038\/bcj.2016.112","article-title":"The role of the proteasome in AML","volume":"6","author":"Csizmar","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2024.03.003","article-title":"Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia","volume":"42","author":"Huang","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Oikonomou, A., Valsecchi, L., Quadri, M., Watrin, T., Scharov, K., Procopio, S., Tu, J.W., Vogt, M., Savino, A.M., and Silvestri, D. (2023). High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia. Biochem. Pharmacol., 217.","DOI":"10.1016\/j.bcp.2023.115809"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Rowland, L., Smart, B., Brown, A., Dettorre, G.M., Gocho, Y., Hunt, J., Yang, W., Yoshimura, S., Reyes, N., and Du, G. (2023). Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio-Protocol, 13.","DOI":"10.21769\/BioProtoc.4731"},{"key":"ref_187","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","article-title":"Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis","volume":"30","author":"Elsallab","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e007118","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of Measurable Residual Disease in Adult Philadelphia Chromosome\u2013Positive ALL: A GRAAPH-2014 Study","volume":"42","author":"Kim","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing\u2013MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/bloodadvances.2023010449","article-title":"Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia","volume":"8","author":"Wieduwilt","year":"2024","journal-title":"Blood Adv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:50Z","timestamp":1760028110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":196,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050779"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050779","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}